NCT02553265View on ClinicalTrials.gov

Carbidopa for the Treatment of Excessive Blood Pressure Variability

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

May 10, 2019

Study Completion Date

May 10, 2019

Conditions
Dysautonomia, FamilialBaroreflex Failure Syndrome
Interventions
DRUG

Carbidopa Low-Dose

300 mg/day

OTHER

Placebo

A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.

DRUG

Carbidopa High-Dose

600 mg/day

Trial Locations (2)

10016

NYU Langone Medical Center, Dyautonomia Center, Suite 9Q, New York

NYU Medical Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02553265 - Carbidopa for the Treatment of Excessive Blood Pressure Variability | Biotech Hunter | Biotech Hunter